Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Meta-analysis

Study investigates antihypertensives in patients with diabetes and kidney disease

esearchers find no survival benefit from any blood pressure-lowering agents in adults with diabetes and kidney disease. In the image, a health worker checks a patient's blood pressure

Source: Shutterstock.com

Researchers undertook a meta-analysis of 157 randomised trials comparing blood pressure lowering drugs in adults with diabetic kidney disease

The comparative efficacy and safety of antihypertensive drugs in adults with diabetes and kidney disease is unclear. To investigate, an international team performed a network meta-analysis of 157 randomised controlled trials with 43,256 participants, including some previously unpublished data.

All studies had at least eight weeks of follow-up and evaluated orally administered blood pressure-lowering drugs.

No blood pressure-lowering strategy prolonged survival in adults with diabetes and kidney disease. However, dual therapy with an angiotensin-receptor blocker (ARB) and an angiotensin converting enzyme inhibitor (ACEi) and ARB monotherapy were each effective for the prevention of end-stage kidney disease, with odds ratios of 0.62 (95% confidence interval [CI] 0.43–0.90) and 0.77 (95% CI 0.65–0.92), respectively, compared with placebo.

Combined ARB/ACEi therapy was ranked lowest for hyperkalaemia and acute kidney injury among all regimens evaluated in the study, published in The Lancet[1] (2015;385:2047–2056). 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068702

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.